

Bin Chen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1849005/bin-chen-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

21
papers

569
citations

12
h-index

23
g-index

25
ext. papers

850
ext. citations

8.8
avg, IF

4.23
L-index

#	Paper	IF	Citations
21	Experimental and real-world evidence supporting the computational repurposing of bumetanide for APOE4-related Alzheimer's disease. <i>Nature Aging</i> , 2021 , 1, 932-947		7
20	Published anti-SARS-CoV-2 in vitro hits share common mechanisms of action that synergize with antivirals. <i>Briefings in Bioinformatics</i> , 2021 , 22,	13.4	2
19	OCTAD: an open workspace for virtually screening therapeutics targeting precise cancer patient groups using gene expression features. <i>Nature Protocols</i> , 2021 , 16, 728-753	18.8	5
18	Analysis of Infected Host Gene Expression Reveals Repurposed Drug Candidates and Time-Dependent Host Response Dynamics for COVID-19 2020 ,		10
17	Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 238-251	24.2	43
16	Gene expression signatures identify paediatric patients with multiple organ dysfunction who require advanced life support in the intensive care unit. <i>EBioMedicine</i> , 2020 , 62, 103122	8.8	3
15	Evaluating cell lines as models for metastatic breast cancer through integrative analysis of genomic data. <i>Nature Communications</i> , 2019 , 10, 2138	17.4	28
14	Leveraging Big Data to Transform Drug Discovery. <i>Methods in Molecular Biology</i> , 2019 , 1939, 91-118	1.4	12
13	Selecting precise reference normal tissue samples for cancer research using a deep learning approach. <i>BMC Medical Genomics</i> , 2019 , 12, 21	3.7	19
12	Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types. <i>Nature Communications</i> , 2019 , 10, 3574	17.4	58
11	Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling. <i>Gastroenterology</i> , 2017 , 152, 2022-2036	13.3	42
10	Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment. <i>JCI Insight</i> , 2017 , 2,	9.9	32
9	Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets. <i>Nature Communications</i> , 2017 , 8, 16022	17.4	85
8	In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma. <i>Oncotarget</i> , 2017 , 8, 4079-4095	3.3	26
7	Integrating Clinical Phenotype and Gene Expression Data to Prioritize Novel Drug Uses. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016 , 5, 599-607	4.5	3
6	Leveraging big data to transform target selection and drug discovery. <i>Clinical Pharmacology and Therapeutics</i> , 2016 , 99, 285-97	6.1	105
5	Relating hepatocellular carcinoma tumor samples and cell lines using gene expression data in translational research. <i>BMC Medical Genomics</i> , 2015 , 8 Suppl 2, S5	3.7	44

4	Relating Chemical Structure to Cellular Response: An Integrative Analysis of Gene Expression, Bioactivity, and Structural Data Across 11,000 Compounds. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015 , 4, 576-84	4-5	37
3	A systematic assessment of linking gene expression with genetic variants for prioritizing candidate targets. <i>Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing</i> , 2015 , 383-94	1-3	2
2	Semantic Breakthrough in Drug Discovery. <i>Synthesis Lectures on the Semantic Web: Theory and Technology</i> , 2014 , 4, 1-142	3-5	4
1	OCTAD: an open workplace for virtually screening therapeutics targeting precise cancer patient groups using gene expression features		2